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Bi-allelic Mutations in NDUFA6
Establish Its Role in Early-Onset
Isolated Mitochondrial Complex I Deficiency
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Isolated complex I deficiency is a common biochemical phenotype observed in pediatric mitochondrial disease and often arises as a
consequence of pathogenic variants affecting one of the 65 genes encoding the complex I structural subunits or assembly factors.
Such genetic heterogeneity means that application of next-generation sequencing technologies to undiagnosed cohorts has been a cata-
lyst for genetic diagnosis and gene-disease associations. We describe the clinical and molecular genetic investigations of four unrelated
children who presented with neuroradiological findings and/or elevated lactate levels, highly suggestive of an underlyingmitochondrial
diagnosis. Next-generation sequencing identified bi-allelic variants inNDUFA6, encoding a 15 kDa LYR-motif-containing complex I sub-
unit that forms part of the Q-module. Functional investigations using subjects’ fibroblast cell lines demonstrated complex I assembly
defects, which were characterized in detail by mass-spectrometry-based complexome profiling. This confirmed a marked reduction in
incorporated NDUFA6 and a concomitant reduction in other Q-module subunits, including NDUFAB1, NDUFA7, and NDUFA12.
Lentiviral transduction of subjects’ fibroblasts showed normalization of complex I. These data also support supercomplex formation,
whereby the 830 kDa complex I intermediate (consisting of the P- and Q-modules) is in complex with assembled complex III
and IV holoenzymes despite lacking the N-module. Interestingly, RNA-sequencing data provided evidence that the consensus RefSeq
accession number does not correspond to the predominant transcript in clinically relevant tissues, prompting revision of the NDUFA6
RefSeq transcript and highlighting not only the importance of thorough variant interpretation but also the assessment of appropriate
transcripts for analysis.Isolated complex I deficiency (OMIM: 252010) is a com-
mon biochemical phenotype observed in pediatric mito-
chondrial disease. The associated clinical and genetic
heterogeneity is vast—individuals can present with a
plethora of clinical symptoms ranging from isolatedmyop-
athy to Leigh syndrome (OMIM: 256000). Complex I is the
first and largest complex of the mitochondrial respiratory
chain and comprises 45 structural subunits with aminimal
contingent of 20 ancillary proteins required for assembly
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(mtDNA) or a nuclear-encoded gene of mitochondrial
function,2 and to date, causative defects have been identi-
fied in 39 genes encoding either complex I structural
subunits or assembly factors.3,4 Additionally, complex I
deficiency can occur as a secondary consequence of
dysfunction involving alternative mitochondrial pro-
cesses.5,6 Application of next-generation sequencing in
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Figure 1. Neuroimaging of Subjects 1 and 2
(A and B) Axial T2 imaging of subject 1 shows diffusely abnormal hyperintensity of the entire whitematter and decreased cortical folding
for her age (A). Signal abnormalities within the brain stem and strikingly low signal affecting red nuclei (arrowheads) are also
apparent (B).
(C) Axial T2 imaging of subject 2 shows extensive signal abnormalities of the cerebral white matter, including the corpus callosum. In
addition, basal ganglia are affected, especially the putamen and caudate nucleus (arrowheads).
(D) Axial FLAIR imaging of subject 2 shows partial cystic degeneration of the affected cerebral white matter (arrowheads).diagnosis of heterogeneous conditions such as mitochon-
drial disease and has been the catalyst for disease-associ-
ated gene discovery through its application to undiag-
nosed cohorts.7 Facilitated by the GeneMatcher tool,8 we
report the findings from four unrelated, clinically affected
children who presented with symptoms suggestive of
mitochondrial disease.
Subject 1, a female infant, was the first child of healthy
non-consanguineous Hungarian parents. On antenatal
anomaly scan, she was noted to be small for her gestational
age and have intracranial ventriculomegaly. Assessment by
fetal medicine confirmed symmetrical growth restriction
on the 3rd percentile, and fetal MRI at 30 weeks of gestation
confirmed ventriculomegaly with mild cerebellar hypopla-
sia. She was born at term (37 þ 3 weeks) by elective
caesarean section for intrauterine growth restriction. Her
birth weight was 1,660 g (<<0.4th percentile [<4 SD]),
and head circumference was 32.5 cm (2nd–9th percentile).
At delivery, she required five inflation breaths and was
initially placed on continuous positive airway pressure.
Venous cord gas showed a pH of 7.25 and a base excess
(BE) of 5.00. Within 40 min, she was self-ventilating in
room air, but a capillary blood gas at that time revealed
metabolic acidosis (pH ¼ 7.12, lactate ¼ 5.9 mmol/L,
BE ¼ 10.2) and hypoglycaemia (blood glucose ¼
1.2 mmol/L). A 10% dextrose infusion (60 mL/kg/day)
was commenced, and benzylpenicillin and gentamicin
were administered. Subsequent capillary blood gas ana-
lyses revealed an improvement in the metabolic acidosis
but persistent hypoglycaemia (pH ¼ 7.31, glucose ¼
1.8 mmol/L). A further bolus of 10% dextrose was admin-
istered before the infusion rate was increased to 90 mL/kg/
day. Although the metabolic acidosis showed some
improvement, the capillary blood lactate remained
elevated (despite boluses of 10% dextrose and 0.9% saline).
Repeat blood analyses revealed clotting abnormalities,
hyperammonaemia (129 mM; normal < 100 mM), and a ris-
ing blood lactate (9.3 mmol/L; normal < 2.2 mmol/L).
An abdominal ultrasound showed echogenic linear areasThe Americain the liver and normal kidneys. A second dose of
vitamin K, followed by fresh-frozen plasma (FFP), sodium
bicarbonate, 0.9% saline bolus, and frusemide, was admin-
istered. Apnoea at around 24 hr of age necessitated intuba-
tion and artificial ventilation before transfer to the
regional neonatal intensive-care unit. Clinical examina-
tion demonstrated severe generalized hypotonia and
absent primitive reflexes. Cerebral function monitoring
(amplitude-integrated electroencephalography) showed a
significantly suppressed baseline and no detectable seizure
pattern. Cranial MRI undertaken at just over 36 hr of age
demonstrated a diffusely abnormal signal intensity of the
entire supratenterial white matter and decreased cortical
folding for her age (Figure 1A), as well as of the brainstem
(Figure 1B) and cerebellar white matter. Over the next
12 hr, despite extensive resuscitative efforts, including
concomitant administration of three different inotropes
(dopamine, dobutamine, and noradrenaline) and further
FFP and packed red cell transfusion, the pupils became
fixed and dilated, and she continued to deteriorate.
Clotting remained abnormal (international normalized
ratio ¼ 3.2; normal < 1.1), although with the exception
of gamma-glutamyl transpeptidase (1,225 IU; normal <
271 IU), liver-function tests were normal. Lactic acidosis
exhibited relentless progression with a blood lactate
reading in excess of 20 mM immediately before death at
approximately 51 hr of age.
Subject 2 is the first son of healthy second-cousin
Kurdish parents, who have a healthy younger daughter.
He was born by normal vaginal delivery at 36 weeks
of gestation (birth weight ¼ 2.8 kg [50th percentile]) after
an uneventful pregnancy. He spoke his first words at
12 months and at 16 months was walking independently.
By 2 years, his parents noted a general physical weakness,
and at 25 months, shortly after an unexplained fever, his
gait deteriorated. Further motor regression and rapid onset
of spasticity of all four limbs followed. He developed
swallowing difficulties and required a gastrostomy tube
for feeding. At 2.5 years, he was bedridden and was unablen Journal of Human Genetics 103, 592–601, October 4, 2018 593
to walk, grasp, or speak. He showed some recovery over
subsequent months, during which he regained several
words, and by 3 years was walking with assistance.
Although there have been no further episodes of rapid
regression, he has slowly deteriorated and has displayed
dysarthric speech andwheelchair dependency from 7 years
of age. Over the last 2 years, he has lost all voluntarymove-
ment in his limbs. Speech is just about understandable,
and cognitive abilities remain good, but his mood is very
low. He has an implanted pump for intrathecal Baclofen
therapy and receives Botox injections every 3 months.
Vison is impaired as a result of optic atrophy, whereas
hearing is normal. Routine laboratory investigations
revealed normal lactate levels in blood (1.2 mmol/L;
normal < 2.2 mmol/L) and cerebrospinal fluid (CSF)
(1.8 mmol/L; normal < 2.4 mmol/L). Light microscopy
and routine histology of skeletal muscle biopsy did not
exhibit any specific findings. Initial cranial MRI showed
extensive and progressive disseminating lesions in supra-
tentorial white-matter regions, including U-fibers and the
corpus callosum, in the basal ganglia, brainstem, and cervi-
cal spinal cord, some of which enhanced with contrast
(Figure 1C). Magnetic resonance spectroscopy revealed
elevated lactate in multiple areas. On follow-up MRI, the
brain abnormalities were less swollen, did not enhance,
and displayed partial cystic degeneration and white-matter
volume loss (Figure 1D).
Subject 3, a male infant, was born to first-cousin South
Asian parents after a pregnancy complicated by oligohy-
dramnios and intrauterine growth restriction. Delivery
was by emergency caesarean section at 36 weeks, and
although he did not require resuscitation at birth, he
was noted to be small for his gestational age (2.27 kg
[9th percentile]) and had minor dysmorphic features,
including an accessory nipple, mild hypospadias, and
sparse, fine scalp hair. At 3 weeks old, he became extremely
irritable but continued to develop normally until
3 months, when he experienced an explosive onset of
seizures. At 5 months old, after being admitted to the hos-
pital for status epilepticus, it was clear that he had lost pre-
viously acquired developmental skills and was exhibiting
truncal hypotonia with limb and facial dystonia. Investi-
gation of his seizure disorder revealed elevated CSF lactate
(5.0 mmol/L; normal < 2.4 mmol/L) and increased T2
signal in the basal ganglia on cranial MRI. Seizures re-
mained problematic despite medical treatment, and he
also suffered significant gastro-esophageal reflux with mul-
tiple episodes of aspiration pneumonia to the extent that
by 2.5 years, he had developed bronchiectasis. Long-
standing neutropenia, first noted at 2 years, was treated
with granulocyte colony-stimulating factor. By 5 years,
his hair had grown thicker and more diffusely on his scalp,
although head growth was poor (0.4th percentile) and
development remained markedly delayed in all domains.
At his current age of 10 years, he sits independently but
is unable to stand or walk. He is mute but responds posi-
tively to familiar voices. Vision is significantly impaired594 The American Journal of Human Genetics 103, 592–601, Octobein relation to bilateral optic atrophy. Re-evaluation of his
symptoms included repeat cranial MRI, which confirmed
progressive changes involving the deep cortical gray mat-
ter of the basal ganglia as well as a more diffuse atrophic
process. A second lumbar puncture showed persistently
elevated CSF lactate (5.6 mmol/L; normal < 2.4 mmol/L),
and analysis of CSF neurotransmitters revealed slightly
low homovanillic acid of 319 IU (normal ¼ 362–955 IU).
Subject 3 has a healthy younger sister. Two male second-
cousins (whose parents are also consanguineous) died at
the ages of 5 and 1.5 years from epilepsy; both were said
to also have abnormal, sparse hair, but no DNA samples
were available for analysis.
Subject 4, a female infant, was the first child of non-
consanguineous white British parents, whose pregnancy
was uneventful. The baby was born at full term by sponta-
neous vaginal delivery, and the baby required no special
care (birth weight ¼ 2.78 kg [>2nd percentile], head
circumference ¼ 34 cm). At 7 weeks, she was admitted to
the hospital after displaying a series of unusual movements
suggestive of a seizure disorder. On admission, infection
was excluded, but high blood gas lactate was noted. She
gradually deteriorated as a result of status epilepticus,
apnoea episodes, and persistent lactic acidosis. Despite
intensive-care management in a tertiary care center, her
lactic acidosis continued until her death at 13 weeks of
age. Blood pH levels ranged from 7.308 to 7.076, blood
gas lactate ranged from 16.9 to 18.5 mmol/L (normal ¼
0.6–1.4 mmol/L), and the CSF lactate level was recorded
at 10.9 mmol/L (normal ¼ 1.1–2.2 mmol/L). MRI shortly
after presentation identified white-matter changes espe-
cially in the corticospinal tract, brain stem, and thalamus.
All clinical indicators were consistent with a diagnosis of
mitochondrial disease, prompting confirmatory genetic
analysis.
Muscle and skin biopsy were taken from subjects 1–3
and referred to local centers for metabolic investigations;
additionally, array comparative genomic hybridization
was performed for subject 3 but revealed no abnormalities.
Respiratory-chain analyses of muscle biopsy confirmed iso-
lated complex I deficiency in subjects 1 and 2 (44% and
46% of control subjects, respectively), whereas analysis
of muscle from subject 3 revealed normal complex I
enzymology despite clinically suggestive features of mito-
chondrial disease. Diagnostic studies of respiratory-chain
complex assembly (2D Blue Native polyacrylamide gel
electrophoresis [BN-PAGE]) were undertaken in fibroblasts
from subject 3 and revealed a marked complex I assembly
defect in isolation, supporting a clinical diagnosis of com-
plex I deficiency. Informed consent for diagnostic and
research studies was obtained for all subjects in accordance
with the Declaration of Helsinki protocols and approved
by local institutional review boards.
Molecular genetic investigations were initiated for
all four subjects—sequencing analysis of the entire mito-
chondrial genome (mtDNA) revealed only wild-type
sequence, suggestive of an underlying Mendelian geneticr 4, 2018
Figure 2. Bi-allelic NDUFA6 Variants Are Identified in Four Unrelated Subjects
(A) Family pedigrees of subjects 1–4 and corresponding sequencing chromatograms presenting compound-heterozygous
c.191G>C (p.Arg64Pro) and c.265G>T (p.Glu89*) NDUFA6 variants in subject 1, the homozygous NDUFA6 deletion c.331_332del
(p.Glu111Serfs*35) in subject 2, the homozygous c.3G>A (p.?) NDUFA6 variant in subject 3, and compound-heterozygous c.309del
(p.Met104Cysfs*35) and c.355del (p.Leu119Tyrfs*20)NDUFA6 frameshift mutations in subject 4. Abbreviations are as follows: S, subject;
C, wild-type control.
(B) Analysis of the resolved crystal structure of complex I revealed spatial proximity of the Arg64 NDUFA6 residue with two negatively
charged and highly conserved NDUFAB1 residues, Lys92 and Asp114. These most likely represent critical binding interactions between
the two proteins during late complex I assembly.
(C) Alignment of the three in-frame NDUFA6 transcripts demonstrates that ENST00000602404 (GenBank: NM_002490.5) uses an initi-
ator methionine downstream of that used by ENST00000498737 (GenBank: NM_002490.4). The shortest transcript, ENST00000470753,
initiates downstream of the highly conserved LYRmotif (shaded yellow) that is reported to be critical for binding the mitochondrial acyl
carrier (encoded by NDUFAB1); the function of this isoform therefore remains unknown. Subject variants are shaded blue.etiology for each subject. Next-generation sequencing
was undertaken in an attempt to elucidate their genetic
diagnosis; a targeted approach was adopted for subject 1,
as previously reported,9 whereas unbiased whole-exome
sequencing was performed for subjects 2 and 3. For subject
2, the exome library was prepared with the Illumina TruSeq
Exome Enrichment Kit and sequenced on a HiSeq 1500;
reads were aligned to the human genome (UCSC Genome
Browser hg19). Bioinformatic analysis was performed as
previously reported.10 Genomic DNA from subject 3 and
his parents was prepared and sequenced as a trio. Library
capture and enrichment was performed with the Nimble-
Gen SeqCap EZ Human Exome Library v.2.0 with subse-
quent sequencing on an Illumina HiSeq platform accord-
ing to the manufacturer’s protocols; data analysis was
performed with Stampy v.1.0.2011 and Platypus v.0.5.2.12
For subject 4 and her parents, whole-genome sequencing
and variant calling were performed as previously
described.13 Trio analysis was performed for de novo, homo-
zygous, compound-heterozygous, and X-linked recessive
inheritance patterns. In addition, mitochondrial genomeThe Americavariants were called and annotated with MToolBox.14
Single-nucleotide variants, indels, structural variants, and
copy-number variants were filtered for frequency (allele
frequency < 1% in population datasets, including gno-
mAD and the ExAC Browser) and for functional impact
(protein-coding changes or non-coding variants previously
reported to be pathogenic in HGMD Professional or Clin-
Var). For each subject, variants were filtered to exclude
those with a minor allele frequency (MAF) in excess of
1%, revealing likely causative variants in an accessory sub-
unit of complex I, NDUFA6 (Figure 2A). Subject 1 harbored
two heterozygous variants within NDUFA6 (GenBank:
NM_002490.5; OMIM: 602138), a c.191G>C transversion
predicted to cause a p.Arg64Pro missense substitution and
a c.265G>T transversion predicted to cause a premature
stop codon, p.Glu89*. Subject 2 was found to harbor a
homozygous 2 bp deletion, c.331_332del, predicted to
cause a p.Glu111Serfs*35 frameshift, whereas subject 3
harbored a homozygous c.3G>A transition predicted to
cause the abolition of the initiation methionine (p.?).
Subject 4 was found to harbor two heterozygous frameshiftn Journal of Human Genetics 103, 592–601, October 4, 2018 595
variants, c.309del (p.Met104Cysfs*35) and c.355del
(p.Leu119Tyrfs*20), in trans. Analysis of parental DNA
samples supported recessive inheritance of each subject’s
NDUFA6 variants; the unaffected sister of subject 2 was het-
erozygous for the familial c.331_332del (p.Glu111Serfs*35)
NDUFA6 variant. The c.265G>T (p.Glu89*) variant
(rs758833609) is reported in two heterozygous individuals
in gnomAD (MAF ¼ 0.0008%). The c.3G>A (p.?) variant
(rs1023075742) is reported in one heterozygous individual
in gnomAD (MAF ¼ 0.0004%), as is the c.355del
(p.Leu119Tyrfs*20) variant (rs781099275). The c.309del
(p.Met104Cysfs*35) variant (rs763006208) is reported in
16 heterozygous individuals in gnomAD (MAF ¼
0.006%). The c.191G>C (p.Arg64Pro) and c.331_332del
(p.Glu111Serfs*35) variants are unreported in gnomAD,
ClinVar, and dbSNP. None of the subjects’ NDUFA6 vari-
ants are reported in the homozygous state in gnomAD,
consistent with a very rare status and offering preliminary
support for a deleterious etiology. All NDUFA6 variants
have been submitted to ClinVar (see Accession Numbers).
The c.3G>A (p.?), c.265G>T (p.Glu89*), c.309del
(p.Met104Cysfs*35), c.331_332del (p.Glu111Serfs*35),
and c.355del (p.Leu119Tyrfs*20) NDUFA6 variants can
be classified as pathogenic according to American College
of Medical Genetics and Genomics guidelines,15 whereas
the c.191G>C (p.Arg64Pro) variant is predicted to be
likely pathogenic. The c.191G>C (p.Arg64Pro) variant af-
fects 1 of 12 evolutionarily conserved arginine residues,
and in silico predictions are strongly supportive of pathoge-
nicity (Align-GVGD ¼ C65, Grantham distance ¼ 102.71,
SIFT ¼ 0.000 [deleterious], PolyPhen ¼ 1.000 [probably
damaging], raw CADD ¼ 7.35, scaled CADD ¼ 34).
CADD scores are often regarded as the most accurate pre-
dictor of pathogenicity, and a scaled CADD score of 34 is
strongly supportive of a deleterious consequence.16 Inves-
tigation of the Protein Databank model of NDUFA6 (PDB:
5XTD.E) confirms that the proximity of the Arg64 residue
to critical residues of NDUFAB1 could inhibit binding of
NDUFAB1 when mutated (Figure 2B). The replacement of
a charged and bulky arginine residue with a small, un-
charged proline residue is unlikely to be tolerated, and
because of its structural conformation, a proline residue
is likely to create a kink in the alpha helix.17 The
c.331_332del variant harbored by subject 2 occurs within
the terminal exon of the gene and is therefore predicted
to evade nonsense-mediated mRNA decay.18 In fact, inves-
tigation of cDNA from fibroblasts showed a normal
amount of NDUFA6 transcript (Figure S1). The encoded
polypeptide is predicted to harbor 34 alternative amino
acids at the C terminus, extending the polypeptide by
17 residues and affecting the tertiary structure of the
mature protein and thus possibly resulting in proteolytic
degradation.
It is noteworthy that NDUFA6 has three reported func-
tional isoforms in UniProt: the first (UniProt: P56556) rep-
resents the longest isoform with 154 residues (GenBank:
NM_002490.4; Ensembl: ENST00000498737.6), the sec-596 The American Journal of Human Genetics 103, 592–601, Octobeond (UniProt: A0A0C4DGSO) has 128 residues (Ensembl:
ENST00000602404.5), and the third (UniProt: R4GN43)
has 71 residues (Ensembl: ENST00000470753.1). All
isoforms occur in frame and use alternative methionine
residues for translation initiation (Figure 2C). Until
now, no consensus on the clinically relevant transcripts
has been reached, but Genotype-Tissue Expression
(GTEx) data and in-house RNA-seq data19 support
ENST00000602404.5 as the predominant isoform, and
RNA expression data specifically correlate with the
50 UTR of ENST00000602404.5 (Figure S2). These data
have led ENST00000602404.5 to now be associated with
the revised accession number GenBank: NM_002490.5.
In order to further characterize the functional conse-
quence of the subjects’ NDUFA6 variants, we undertook
functional investigations with fibroblast cell lines from
each subject for whom tissues were available (S1–S3).
High-resolution respirometry of subject fibroblasts was
performed with the Oroboros 2k platform as described pre-
viously20 and revealed a remarkable impairment of intact
cell respiration in subject 1. Intact cell respiration of sub-
jects 2 and 3 was almost comparable to that of control fi-
broblasts (Figure S3). BN-PAGE of enriched mitochondrial
fractions from subject fibroblasts and age-matched control
cell lines was performed as previously reported.21 Immu-
noblotting using antibodies conjugated against structural
subunits from each OXPHOS complex (complex I
[NDUFB8], complex II [SDHA], complex III [UQCRC2,
core 2], complex IV [MT-CO1], and complex V [ATP5F1A])
revealed a reduction of fully assembled complex I levels,
whereas all other OXPHOS complexes were unaffected.
Complex I subcomplexes, consistent with stalled assembly
intermediates, were apparent in the subjects’ cell lines, but
not in control cells (Figure 3A). Subject 1, who presented
with the most aggressive clinical course, had the most
marked reduction in fully assembled complex I, whereas
subjects 2 and 3 (whose presentations were less severe)
also had impaired complex I assembly, although to a lesser
extent. Steady-state levels of complex I structural compo-
nents were assessed with SDS-PAGE of subject and
control fibroblast cell lysates according to previous meth-
odologies.21 Immunoblotting using antibodies conjugated
against various structural subunits of complex I (NDUFV1,
NDUFA13, MT-ND1, NDUFA9 and NDUFB8) revealed a
marked reduction in the steady-state levels of complex I
subunits for subject 1, whereby the N module and Q mod-
ule subunits were most affected (Figure 3B). A similar but
milder pattern was observed for subjects 2 and 3, consis-
tent with BN-PAGE analyses (Figure 3B). SDH70 (SDHA
of complex II) and porin were used asmarkers. Immunoflu-
orescence staining of fibroblasts with NDUFS4 as a marker
of complex I expression revealed lower expression of com-
plex I protein in subject 2 than in age-matched controls
subjects (Figure S4). Given that pathogenic variants have
not previously been reported in NDUFA6, fibroblast cell
lines from subjects 1–3 were subject to lentiviral rescue as
previously described.24 Subsequent analysis by BN-PAGEr 4, 2018
Figure 3. BN-PAGE, SDS-PAGE, and Complementation Studies
(A) Mitochondria isolated from cultured skin fibroblasts from subjects 1–3 and age-matched control subjects were solubilized in
n-dodecyl b-D-maltoside (DDM) and subjected to BN-PAGE and immunoblotting analysis using antibodies directed to various OXPHOS
complexes as indicated. The blot probed with an antibody raised against NDUFB8 revealed the presence of additional, partially assem-
bled complex I intermediates in the samples from subjects 1–3 (indicated by an asterisk) but not in control samples.
(B) Whole-fibroblast cell lysates from subjects 1–3 and age-matched control subjects were analyzed by SDS-PAGE. Immunoblotting was
performed with antibodies against complex I subunits or control proteins (SDHA and porin) as indicated. Complex I structural subunits
are color coded according to their corresponding complex I modules, as illustrated in the complex I pictogram.
(C) Wild-type NDUFA6 cDNA was generated and introduced into control and subject cell lines via retroviral expression. Whole-cell
lysates were solubilized in 1% Triton X-100 (immunoblotting) before BN-PAGE analysis. Immunoblotting using antibodies against
the complex I subunit NDUFA9 (top) and the complex II subunit SDHA (bottom) as a loading control revealed less complex I in subject
cell lines than in control cell lines. After transfection with NDUFA6, complex I levels were restored.
(D) In-gel activity analysis was performed according to Zerbetto et al.22 withmitochondria isolated from the fibroblasts of subjects 1 (S1)
and 3 (S3) with (þ) and without () lentiviral transduction with NDUFA6 cDNA and an aged-matched control subject; enriched
mitochondria were solubilized in 1% digitonin for BN-PAGE analysis, which demonstrated restoration of complex I activity in
subjects 1 and 3 after the introduction of NDUFA6 (top). The gel was then stained with colloidal Coomassie according to Neuhoff
et al.23 as a loading control (bottom). All antibodies used are documented in Table S1.confirmed that transduction of all three subject cell lines
with a wild-type NDUFA6 cDNA transcript ameliorated
the complex I assembly defect, unequivocally establishing
the subjects’ NDUFA6 variants as the cause of disease
(Figure 3C). In-gel activity assay of enriched mitochondria
derived from the fibroblast cell lines from subjects 1 and 3
recapitulated the phenotypic rescue with restoration of
complex I activity (Figure 3D); analysis of the fibroblast
cell line from subject 2 was attempted but was unsuccessful
because cells failed to grow.
To further delineate the consequence of the subjects’
NDUFA6 variants on mitochondrial complex I assembly,
we undertook complexome profiling of age-matched con-
trol cells (Figure 4A) and subject fibroblasts (Figure 4B)
as previously described.26,27 Analysis of complexome
profiling data recapitulated the assembly defect observed
after BN-PAGE analysis of fibroblasts from subjects 1–3 (Fig-
ures 4B and 4C). A clear reduction of N-module subunits
was visible, particularly in the most severely affected indi-
vidual, subject 1 (Figure 4B, boxed area), correlating the as-The Americasembly defect with the observed phenotypic severity. A loss
of NDUFA7 andNDUFA12 from the subcomplex is evident,
particularly in subject 1, and appears to correlate with the
degree of NDUFA6 loss. It is possible that NDUFA6 is a pre-
requisite forNDUFA7andNDUFA12 incorporation into the
complex I holoenzyme and that absence of NDUFA6 or its
impaired function results in stalling and prevents subse-
quent interactions with the subunits of the N-module.
Loss (subject 1; Figure 4B) or marked reduction (subjects 2
and 3; Figures 4C and 4D) of the mitochondrial acyl carrier
(NDUFAB1) from complex I is also evident from complex-
ome profiling data; this is unsurprising given that the LYR
motif of NDUFA6 has been demonstrated to be critical for
NDUFAB1 binding in the model aerobic yeast, Yarrowia
lipolytica.28 Interestingly, the complexome profiling data
provide evidence of NDUFAF2, a late-stage complex I
assembly factor, still bound to the stalled assembly interme-
diate (Figure S5); this has previously been observed
as a consequence of pathogenic mutations affecting
N-module subunitsNDUFV1 (OMIM: 161015) andNDUFS4n Journal of Human Genetics 103, 592–601, October 4, 2018 597
Figure 4. Complexome Profiling of Fibroblasts from Subjects 1–3 Identifies Stalled Complex I Assembly Intermediates
Control (A), subject 1 (B), subject 2 (C), and subject 3 (D). The left lane indicates assembly factors (gray) and structural subunits (orange-
brown) of complex I modules, complex III (red), and complex IV (green). Dashed boxes indicate the loss or reduction of N-module sub-
units in subject fibroblast lines. White arrows highlight the loss or reduction of NDUFA6, NDUFA7 and NDUFA12 from complex I in
subjects 1–3, and blue arrows indicate the location of NDUFAF2, still bound to the stalled complex I intermediate in subject complex-
omes but not in the control. Assignment of complex I subunits to modules was according to Wirth et al.25 Intensity-based absolute
quantification (iBAQ) values were normalized to the sum of all values of the control. Native mass calibration was performed according
to Fuhrmann et al.26(OMIM: 602694).29 The failure of NDUFAF2 to dissociate
from the stalled assembly intermediate (830 kDa) after
mutation of either N-module or Q-module subunits sup-
ports the theory that dissociation of NDUFAF2 represents
a key checkpoint in complex I holoenzyme assembly.30
Despite the absence of N-module subunits, subject com-
plexome data support an ability of the 830 kDa intermedi-
ate (plus bound NDUFAF2) to participate in supercomplex
formation, whereby fully assembled complexes III and IV
appear in complex with the P- and Q-modules of
complex I (minus NDUFA6, NDUFA7, NDUFA12, and the
Q-module associated copy of NDUFAB1). This supercom-
plex (I830/III2/IV1-4) does not represent a functional respira-
some given its apparent lack of NADH dehydrogenase
activity but is consistent with other findings showing that
N-module subunits are not needed to act as scaffolding
during supercomplex assembly.31,32 This is also supported
by the fact that not a single subunit of the N-module inter-
actswith any of the structural subunits of either complex III
or IV in the resolved native supercomplexes.33598 The American Journal of Human Genetics 103, 592–601, OctobeRecently identified disease-related genes associated
with a biochemical manifestation of complex I deficiency
include the assembly factors TIMMDC1 (OMIM:
615534)19 andTMEM126B (OMIM: 615533),34,35 the gluta-
thione transporter SLC25A10 (OMIM: 606794),36 and
EXOSC3 (OMIM: 606489), a subunit of the human RNA
exosome complex.37 The connection between an apparent
isolated complex I deficiency and the putative genetic
defect is oftennot clear cut and can in fact occur as a second-
ary consequence of mitochondrial dysfunction in another
pathway. For example, bi-allelic pathogenic variants in
MTFMT (OMIM: 611766), encoding amitochondrialmeth-
yltransferase that formylates methionine residues for use
in mitochondrial protein initiation, often results in an
isolated complex I deficiency despite affecting multiple
OXPHOS complexes.38 The isolated complex I deficiency
observed in fibroblasts from subjects 1 and 2 is consistent
with the bi-allelic NDUFA6 variants identified given that
NDUFA6 encodes an accessory structural subunit of com-
plex I. Importantly,NDUFA6 is oneof 27 accessory subunitsr 4, 2018
thathavebeen showntobe essential for complex I assembly
and activity.32 Subject 3, who lacks biochemical evidence of
complex I dysfunction, remains somewhat enigmatic,
particularly given that his homozygous NDUFA6 variant is
predicted to abolish the initiation methionine. It is com-
mon for subject fibroblasts to demonstrate normal complex
I activities despite a marked deficiency in a clinically rele-
vant tissue (e.g., skeletalmuscle),39 but the situation for sub-
ject 3—normal enzymatic activity in muscle despite a
demonstrable complex I assembly defect—ismost unusual.
Although the fibroblast cell line from subject 3 also demon-
strated normal complex I activity (data not shown), a clear
growth defect was demonstrated when glucose-rich culture
mediumwas replacedwith galactose-rich (and glucose-free)
medium, forcing the cells to be dependent upon oxidative
phosphorylation for ATP production (Figure S6). The exis-
tence of the longer NDUFA6 isoform (UniProt: P56556)
could explain the normal complex I activity reported for
subject 3,whose variantwould instead act as a homozygous
missense variant in the encoding transcript (c.81G>A
[p.Met27Ile]). In silico predictions suggest that the
c.81G>A (p.Met27Ile) variant might be tolerated (Align-
GVGD ¼ C0, Grantham distance ¼ 10.12, SIFT ¼
0.070 [tolerated], PolyPhen ¼ 0.702 [possibly damaging],
CADD ¼ 34). The CADD score discordance is most likely
due to the consideration of alternative transcripts in the
prediction and is therefore exacerbated by the pathoge-
nicity associated with the initiation methionine in the
alternative transcript. Attempts to assess whether an alter-
native methionine was selected for translation initiation
in vivohave beenunsuccessful; analysis of tryptic fragments
of subject proteins produced during complexome profiling
was uninformative, and commercially available antibodies
have failed to conjugate successfullywith the target protein
in subject and control tissues (data not shown). Another
possibility is that NDUFA6 translation is subject to ‘‘leaky’’
initiation and thus results in selection of various in-frame
methionine residues for translation initiation; this would
result in the co-existence of Met1- and Met27-containing
NDUFA6 polypeptides in the human mitoproteome and,
in the context of subject 3, would dilute the pathogenic
etiology. The additional isoform (P56556) is not anticipated
to ameliorate the pathogenicity of the NDUFA6 variants
harbored by subject 1 or 2—their variants are predicted to
exert the same effect in an isoform-independent manner.
This report describes bi-allelic NDUFA6 variants in four
pediatric subjects who each have a clinical diagnosis of
mitochondrial disease. For the three subjects with available
tissues, associated complex I assembly defects were demon-
strated together with lentiviral rescue of the biochemical
phenotype. This study therefore establishes NDUFA6 as
the 29th structural subunit of complex I to be associated
with human pathology. Given that one subject had
normal complex I activity in skeletal muscle, this report
epitomizes the importance of an unbiased approach
to genetic diagnosis. Thorough variant interpretation and
assessment of appropriate transcripts remain both an obli-The Americagation and a challenge for the diagnostic community in
this genomic era.Accession Numbers
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